Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
3.
J Anal Toxicol ; 47(6): 495-503, 2023 Jul 22.
Artículo en Inglés | MEDLINE | ID: mdl-37079848

RESUMEN

Maternal drug use during pregnancy has significant health and socio-legal implications. The Substance Abuse and Mental Health Services Administration publishes self-reported rates of drug use during pregnancy; however, comprehensive long-term laboratory data on neonatal drug exposure are lacking. Over 175,000 meconium specimens originating from 46 US states were analyzed at ARUP Laboratories between the years 2015 and 2020. A retrospective investigation of drug positivity rates, multidrug detection and median drug concentrations was conducted for 28 compounds in six drug classes. The overall meconium drug positivity rate was lowest in 2015 (47.3%), which increased over 6 years, reaching a peak in 2020 (53.4%). 11-Nor-9-carboxy-tetrahydrocannabinol (THC-COOH) was the most frequently detected compound across all 6 years. The second most frequently detected analyte was morphine in 2015-2016 and amphetamines in 2017-2020. The THC-COOH positivity rate rose from 29.7% in 2015 to 38.2% in 2020. The positivity rates for stimulants also increased in the range of 0.4-2.9% in 2020 compared to 2015. Conversely, opioid positivity rates declined in the range of 1.6-2.3% in 2020 as compared to 2015. The most common two-drug combination was THC-COOH-opioids (2.4%) in 2015-2016, which was replaced by THC-COOH-amphetamines (2.6%) in 2017-2020. The most common three-drug combination was THC-COOH-opioids-amphetamines throughout all 6 years. Neonatal drug exposure positivity rates have increased over the past 6 years based on retrospective data analysis from the patient population submitted for testing at ARUP Laboratories.


Asunto(s)
Analgésicos Opioides , Meconio , Recién Nacido , Embarazo , Femenino , Humanos , Meconio/química , Analgésicos Opioides/análisis , Estudios Retrospectivos , Cromatografía de Gases y Espectrometría de Masas , Detección de Abuso de Sustancias , Dronabinol/análisis , Anfetaminas/análisis
5.
J Anal Toxicol ; 47(1): 96-105, 2023 Feb 21.
Artículo en Inglés | MEDLINE | ID: mdl-35707888

RESUMEN

Maternal drug use during pregnancy is a significant concern. Drug-exposed newborns are often born premature and may suffer from birth defects, neonatal abstinence syndrome and cognitive and developmental delays. Because of this, testing of neonatal specimens is carried out to assess fetal drug exposure during pregnancy. Umbilical cord tissue (UC) and meconium are commonly used specimens for this purpose. However, comprehensive studies comparing drug positivity rates and concentration in the two specimen types are lacking. To this end, 4,036 paired UC and meconium specimens originating from 13 states within the USA were identified, and retrospective analysis of drug positivity rates and drug concentration was performed for 31 analytes in 5 drug classes. Testing for 11-Nor-9-carboxy-tetrahydrocannabinol (THC-COOH) is a separate orderable for UC specimen at our laboratory, so a second data set was created for evaluation of this drug analyte with 2,112 paired UC and meconium specimens originating from 11 states. Testing of UC was performed by semi-quantitative liquid chromatography-tandem mass spectrometry (LC-MS-MS) assays, whereas, for meconium, an immunoassay-based screening preceded LC-MS-MS confirmation tests. Results generated for UC and meconium specimens were therefore compared for a total of 32 drug analytes from 6 drug classes. Drug concentrations for analytes were higher in meconium compared to UC, with the exception of phencyclidine. Despite this, the positivity rates for individual analytes were higher in UC, with the exception of THC-COOH and cocaine. Furthermore, analysis for multidrug positivity revealed that THC-COOH and opioids were the most common multidrug combination detected in both matrices. In conclusion, this study suggests that for most drug compounds, UC was more analytically sensitive to assess neonatal drug exposure by current methodologies. Additionally, by demonstrating that meconium has higher drug concentrations for most compounds, this study sets the stage for developing more sensitive assays in meconium.


Asunto(s)
Cocaína , Meconio , Recién Nacido , Embarazo , Humanos , Femenino , Meconio/química , Estudios Retrospectivos , Detección de Abuso de Sustancias/métodos , Cocaína/análisis , Cordón Umbilical
6.
J Appl Lab Med ; 8(2): 341-346, 2023 03 06.
Artículo en Inglés | MEDLINE | ID: mdl-36373410

RESUMEN

BACKGROUND: Many low-complexity urine drug screen (UDS) devices are approved by the Food and Drug Administration as waived under Clinical Laboratory Improvement Amendments (CLIA) criteria. Labeling instructs patients to urinate directly into the device and also states that positive results should be confirmed. However, the device itself may pose a risk of drug adsorption and/or specimen contamination that could affect results in confirmatory assays if specimens are reused. Collecting urine in a separate container before performing the UDS would reclassify the test as nonwaived, negating the conveniences of a CLIA-waived test. Also, patients may be unable or unwilling to urinate in an additional container for confirmatory testing. This study examined reusing urine from a UDS device (NexScreen) for confirmatory testing. METHODS: 25 patient specimens were pooled and verified to be drug-free. To evaluate drug leaching from the UDS device, 30 mL of this pool was incubated in NexScreen cups, followed by confirmatory testing. To evaluate drug adsorption, 14 representative analytes were spiked slightly over the NexScreen positivity cutoffs, followed by incubation in NexScreen cups and confirmation testing. RESULTS: All negative samples incubated in NexScreen cups remained negative upon confirmation testing, indicating that NexScreen test strips do not contaminate the specimen. For the drug adsorption experiment, 11 of 14 analytes had recoveries of at least 95%, whereas buprenorphine and 11-nor-9-carboxy-tetrahydrocannabinol recovered at 94% and 87%, respectively, suggesting minor adsorption. All analytes recovered above their respective confirmation cutoffs. CONCLUSIONS: Urine aliquots from NexScreen cups may be used for confirmatory testing.


Asunto(s)
Servicios de Laboratorio Clínico , Laboratorios Clínicos , Estados Unidos , Humanos , Laboratorios , Bioensayo , Dronabinol
7.
Clin Biochem ; 115: 97-102, 2023 May.
Artículo en Inglés | MEDLINE | ID: mdl-36356659

RESUMEN

Ethanol is a volatile substance, and specimens need to be tightly capped prior to analysis to prevent evaporative loss. However, add-on requests in previously decapped tubes are commonly received, yet ethanol stability in this setting is unclear. We compared the stability of ethanol in capped vs decapped tubes in the context of routine laboratory automation, storage time, and specimen volumes. Serum specimens were pooled and spiked with ethanol followed by simulating an add-on scenario. Additionally, to evaluate ethanol stability at room temperature for extended times, ethanol concentrations were measured in capped or decapped tubes containing 0.5 mL or 0.1 mL samples over a 4 h time course. Finally, the risk of misclassification of ethanol results in decapped tubes was evaluated near the critical value threshold (∼54 mmol/L). The add-on tubes had a mean recovery of 101.5 % (95 % CI: 97.7-105.4 %) relative to the direct tubes. The time-course experiment showed an average recovery of 87.4 % (95 % CI: 81.8-94.0 %) at the 4 h time point in decapped 0.5 mL specimens. An average recovery of 85.4 % (95 % CI: 84.2-86.1 %) was observed for specimens spiked near the critical value threshold. Importantly, all measurements with 0.5 mL specimen volume were within 25 %, which is the total allowable error (TAE) of the assay.However, with a 0.1 mL volume, specimens cross the TAE threshold just after 1 h, and the percent recovery at 4 h dropped to 52.9 % (95 % CI: 50.2-55.7 %). In conclusion, ethanol testing in decapped tubes remains within the TAE for up to 4 h in specimens with a 0.5 mL volume. Therefore, add-on ethanol testing using routine laboratory automation and storage conditions can be successfully performed.


Asunto(s)
Etanol , Humanos , Factores de Tiempo , Pruebas de Coagulación Sanguínea
8.
Methods Mol Biol ; 2546: 175-183, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36127588

RESUMEN

Homovanillic acid (HVA) and vanillylmandelic acid (VMA) are catecholamine metabolites used in the diagnostic workup of neuroendocrine tumors. Here we describe a simple dilute-and-shoot method for simultaneously quantitating HVA and VMA in human urine specimens. The method employs analyte separation on a reverse-phase liquid chromatography column followed by detection using electrospray ionization triple quadrupole mass spectrometry (ESI-MS/MS), wherein qualifier and quantifier ion transitions are monitored. This is a simple and fast analytical method with an injection-to-injection time of 4 min.


Asunto(s)
Espectrometría de Masas en Tándem , Ácido Vanilmandélico , Catecolaminas , Cromatografía Liquida/métodos , Ácido Homovanílico/química , Ácido Homovanílico/orina , Humanos , Espectrometría de Masas en Tándem/métodos , Ácido Vanilmandélico/orina
9.
Eur J Drug Metab Pharmacokinet ; 47(5): 725-740, 2022 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-35881329

RESUMEN

BACKGROUND AND OBJECTIVES: Desidustat is a novel prolyl hydroxylase domain (PHD) inhibitor for the treatment of anemia. The objective of this study was to investigate the pharmacokinetics and drug-drug interaction properties of desidustat using in vitro and in vivo nonclinical models. METHODS: In vitro, Caco2 cell permeability, plasma protein binding, metabolism, cytochrome P450 (CYP) inhibition, and CYP induction were examined. In vivo, pharmacokinetic studies of oral bioavailability in mice, rats, dogs and monkeys, dose linearity, tissue distribution, and excretion in rats were conducted. RESULTS: In Caco-2 cells, the apparent permeability of desidustat was high at low pH and low at neutral pH. The oral bioavailability (%F) of desidustat was 43-100% with a median time to reach peak concentration (Tmax) of about 0.25-1.3 h across species. Desidustat displayed a low mean plasma clearance (CL) of 1.3-4.1 mL/min/kg (approximately 1.8-7.4% of hepatic blood flow), and the mean steady-state volume of distribution (Vss) was 0.2-0.4 L/kg (approximately 30-61% of the total body water). Desidustat showed a dose-dependent increase in exposures over the 15-100 mg/kg dose range. It was rapidly distributed in various tissues, with the highest tissue-to-blood ratio in the liver (1.8) and kidney (1.7). Desidustat showed high plasma protein binding and was metabolically stable in human liver microsomes, hepatocytes, and recombinant CYPs. It did not show significant inhibition of major drug-metabolizing CYP enzymes (IC50 > 300 µM) or the potential to induce CYP1A2 and CYP3A4/5 (up to 100 µM) in HepG2 cells. It may have minimal potential of clinical drug-drug interaction when used in combination with iron supplements or phosphate binders. Desidustat was primarily excreted unchanged in urine (25% of the oral dose) and bile (25% of the oral dose) in rats. The mean elimination half-life of desidustat ranged from 1.0 to 5.3 h and 1.3 to 5.7 h across species after intravenous and oral administration, respectively. CONCLUSION: Taken together, desidustat is well absorbed orally. It showed a dose-dependent increase in exposure, did not accumulate in tissue, and was eliminated via dual routes. It is metabolically stable, has minimal potential to cause clinical drug-drug interactions (DDIs), and demonstrates discriminable pharmacokinetic properties for the treatment of anemia.


Asunto(s)
Anemia , Inhibidores de Prolil-Hidroxilasa , Administración Oral , Anemia/metabolismo , Animales , Células CACO-2 , Sistema Enzimático del Citocromo P-450/metabolismo , Perros , Humanos , Ratones , Microsomas Hepáticos/metabolismo , Inhibidores de Prolil-Hidroxilasa/farmacología , Quinolonas , Ratas
10.
Clin Biochem ; 96: 78-81, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34246633

RESUMEN

Lipid panels are a commonly performed test in clinical laboratories. Due to the high prevalence of cardiovascular diseases around the world, it is common to see serum or plasma specimens with high results for one or more components of the lipid panel. Exceedingly low results, however, are rare and may be attributed to certain genetic, infectious, or autoimmune conditions in addition to analytical interference. Here we report a serum specimen from a 58-year-old female with cholesterol and triglyceride values below the detection limit of the assay, which was investigated to identify the cause of the anomaly. Using vitamin C test strips and high-performance liquid chromatography, the presence of high levels of antioxidant vitamin C in the patient specimen was confirmed. Subsequent treatment of the sample with the enzyme ascorbate oxidase inactivated vitamin C, leading to lipid analyte values falling within the expected range upon repeat analysis. Thus, analytical interference by vitamin C should be considered when suspiciously low lipid panel results are encountered.


Asunto(s)
Colesterol/sangre , Triglicéridos/sangre , Antioxidantes/metabolismo , Ácido Ascórbico/sangre , Femenino , Humanos , Persona de Mediana Edad
11.
Nat Commun ; 12(1): 2939, 2021 05 19.
Artículo en Inglés | MEDLINE | ID: mdl-34011960

RESUMEN

Elucidation of non-canonical protein functions can identify novel tissue homeostasis pathways. Herein, we describe a role for the Bcl-2 family member BAD in postnatal mammary gland morphogenesis. In Bad3SA knock-in mice, where BAD cannot undergo phosphorylation at 3 key serine residues, pubertal gland development is delayed due to aberrant tubulogenesis of the ductal epithelium. Proteomic and RPPA analyses identify that BAD regulates focal adhesions and the mRNA translation repressor, 4E-BP1. These results suggest that BAD modulates localized translation that drives focal adhesion maturation and cell motility. Consistent with this, cells within Bad3SA organoids contain unstable protrusions with decreased compartmentalized mRNA translation and focal adhesions, and exhibit reduced cell migration and tubulogenesis. Critically, protrusion stability is rescued by 4E-BP1 depletion. Together our results confirm an unexpected role of BAD in controlling localized translation and cell migration during mammary gland development.


Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/metabolismo , Proteínas de Ciclo Celular/metabolismo , Glándulas Mamarias Animales/crecimiento & desarrollo , Glándulas Mamarias Animales/metabolismo , Glándulas Mamarias Humanas/crecimiento & desarrollo , Glándulas Mamarias Humanas/metabolismo , Proteína Letal Asociada a bcl/metabolismo , Sustitución de Aminoácidos , Animales , Línea Celular , Movimiento Celular/genética , Femenino , Técnicas de Sustitución del Gen , Humanos , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Modelos Animales , Morfogénesis , Proteínas Mutantes/química , Proteínas Mutantes/genética , Proteínas Mutantes/metabolismo , Organoides/crecimiento & desarrollo , Organoides/metabolismo , Fosforilación , Biosíntesis de Proteínas , ARN Mensajero/genética , ARN Mensajero/metabolismo , Serina/química , Proteína Letal Asociada a bcl/deficiencia , Proteína Letal Asociada a bcl/genética
12.
Molecules ; 25(17)2020 Aug 24.
Artículo en Inglés | MEDLINE | ID: mdl-32847114

RESUMEN

Resveratrol (3,4,5-Trihydroxy-trans-stilbene) is a naturally occurring polyphenol that exhibits beneficial pleiotropic health effects. It is one of the most promising natural molecules in the prevention and treatment of chronic diseases and autoimmune disorders. One of the key limitations in the clinical use of resveratrol is its extensive metabolic processing to its glucuronides and sulfates. It has been estimated that around 75% of this polyphenol is excreted via feces and urine. To possibly alleviate the extensive metabolic processing and improve bioavailability, we have added segments of acetylsalicylic acid to resveratrol in an attempt to maintain the functional properties of both. We initially characterized resveratrol-aspirin derivatives as products that can inhibit cytochrome P450 Family 1 Subfamily A Member 1 (CYP1A1) activity, DNA methyltransferase (DNMT) activity, and cyclooxygenase (COX) activity. In this study, we provide a detailed analysis of how resveratrol and its aspirin derivatives can inhibit nuclear factor kappa B (NFκB) activation, cytokine production, the growth rate of cancer cells, and in vivo alleviate intestinal inflammation and tumor growth. We identified resveratrol derivatives C3 and C11 as closely preserving resveratrol bioactivities of growth inhibition of cancer cells, inhibition of NFκB activation, activation of sirtuin, and 5' adenosine monophosphate-activated protein kinase (AMPK) activity. We speculate that the aspirin derivatives of resveratrol would be more metabolically stable, resulting in increased efficacy for treating immune disorders and as an anti-cancer agent.


Asunto(s)
Antiinflamatorios/farmacología , Antineoplásicos/farmacología , Aspirina , Neoplasias del Colon/tratamiento farmacológico , Inhibidores Enzimáticos , Proteínas de Neoplasias/antagonistas & inhibidores , Resveratrol , Animales , Aspirina/análogos & derivados , Aspirina/química , Aspirina/farmacología , Neoplasias del Colon/enzimología , Neoplasias del Colon/patología , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Células HCT116 , Humanos , Ratones , Proteínas de Neoplasias/metabolismo , Resveratrol/análogos & derivados , Resveratrol/química , Resveratrol/farmacología
13.
Cell Death Dis ; 11(6): 448, 2020 06 11.
Artículo en Inglés | MEDLINE | ID: mdl-32528057

RESUMEN

Apoptosis is fundamental to normal animal development and is the target for many anticancer therapies. Recent studies have explored the consequences of "failed apoptosis" where the apoptotic program is initiated but does not go to completion and does not cause cell death. Nevertheless, this failed apoptosis induces DNA double-strand breaks generating mutations that facilitate tumorigenesis. Whether failed apoptosis is relevant to clinical disease is unknown. BCL-2 interacting killer (BIK) is a stress-induced BH3-only protein that stimulates apoptosis in response to hormone and growth factor deprivation, hypoxia, and genomic stress. It was unclear whether BIK promotes or suppresses tumor survival within the context of breast cancer. We investigated this and show that BIK induces failed apoptosis with limited caspase activation and genomic damage in the absence of extensive cell death. Surviving cells acquire aggressive phenotypes characterized by enrichment of cancer stem-like cells, increased motility and increased clonogenic survival. Furthermore, by examining six independent cohorts of patients (total n = 969), we discovered that high BIK mRNA and protein levels predicted clinical relapse of Estrogen receptor (ER)-positive cancers, which account for almost 70% of all breast cancers diagnosed but had no predictive value for hormone receptor-negative (triple-negative) patients. Thus, this study identifies BIK as a biomarker for tumor recurrence of ER-positive patients and provides a potential mechanism whereby failed apoptosis contributes to cancer aggression.


Asunto(s)
Neoplasias de la Mama/genética , Proteína Destructora del Antagonista Homólogo bcl-2/metabolismo , Apoptosis , Neoplasias de la Mama/mortalidad , Femenino , Humanos , Fenotipo , Pronóstico , Análisis de Supervivencia
14.
J Med Chem ; 61(24): 10976-10995, 2018 12 27.
Artículo en Inglés | MEDLINE | ID: mdl-30010338

RESUMEN

The nuclear receptor retinoic acid receptor-related orphan receptor gamma (RORγ or RORc) is a key transcription factor for the production of pro-inflammatory cytokines implicated in the pathogenesis of autoimmune diseases. Recently, small molecule inhibitors of RORc drew the enormous attention of the research community worldwide as a possible therapy for autoimmune diseases, mediated by the IL-17 cytokine. With the clinical proof-of-concept inferred from a small molecule inhibitor VTP-43742 for psoriasis and recent inflow of several RORc inhibitors into the clinic for therapeutic interventions in autoimmune diseases, this field continues to evolve. This review briefly summarizes the RORc inhibitors disclosed in the literature and discusses the progress made by these inhibitors in combating autoimmune diseases.


Asunto(s)
Enfermedades Autoinmunes/tratamiento farmacológico , Miembro 3 del Grupo F de la Subfamilia 1 de Receptores Nucleares/antagonistas & inhibidores , Sulfonamidas/química , Amidas/química , Amidas/farmacología , Ensayos Clínicos como Asunto , Humanos , Miembro 3 del Grupo F de la Subfamilia 1 de Receptores Nucleares/química , Piridinas/química , Piridinas/farmacología , Pirrolidinas/química , Pirrolidinas/farmacología , Sulfonamidas/farmacología
15.
J Med Chem ; 61(16): 6964-6982, 2018 08 23.
Artículo en Inglés | MEDLINE | ID: mdl-29712435

RESUMEN

Chronic kidney disease, cancer, chronic inflammatory disorders, nutritional, and genetic deficiency can cause anemia. Hypoxia causes induction of hypoxia-inducible factor (HIF), which stimulates erythropoietin (EPO) synthesis. Prolyl hydroxylase domain (PHD) enzyme inhibition can stabilize hypoxia-inducible factor (HIF). HIF stabilization also decreases hepcidin, a hormone of hepatic origin, which regulates iron homeostasis. PHD inhibitors represent a novel pharmacological treatment of anemia associated with chronic diseases. Many orally active PHD inhibitors like roxadustat, molidustat, vadadustat, and desidustat are in late phase clinical trials. This review discusses the role of PHD inhibitors in the treatment of anemia associated with chronic diseases.


Asunto(s)
Anemia/tratamiento farmacológico , Enfermedades Genéticas Congénitas/tratamiento farmacológico , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Neoplasias/tratamiento farmacológico , Inhibidores de Prolil-Hidroxilasa/farmacología , Insuficiencia Renal Crónica/tratamiento farmacológico , Humanos , Inhibidores de Prolil-Hidroxilasa/química
16.
Xenobiotica ; 48(1): 37-44, 2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-28042744

RESUMEN

1. ZYAN1 is a prolyl hydroxylase inhibitor in clinical development for treatment of anemia associated with chronic kidney disease (CKD). We evaluated the effect of acute and chronic kidney impairment on the pharmacokinetics of ZYAN1 in rat models. 2. Cisplatin (2.5, 5 and 7.5 mg/kg) was used to induce acute kidney injury (AKI), and five-sixth and total nephrectomy was used to induce chronic kidney injury (CKI) in male Wistar rats. All groups received a single 15 mg/kg oral dose of ZYAN1. Blood/urine samples were analyzed for ZYAN1 to assess peak concentration (Cmax), area under the concentration-time curve (AUCinf), total body clearance (CL/F) and elimination half-life (T1/2). 3. Cmax and AUCinf were not significantly different in the various AKI groups or in five-sixth nephrectomized rats, as compared to control rats. Recovery of ZYAN1 in urine was reduced; the impact on the CL/F was minimal. There was a 2-fold increase in AUCinf with reduction in CL/F in total nephrectomized rats. T1/2 was longer for ZYAN1 in the severe AKI/five-sixth nephrectomy rats and total nephrectomy rats as compared to control rats. 4. Based on the rodent data it may be inferred that PK of ZYAN1 in CKD patients may be minimally affected.


Asunto(s)
Fallo Renal Crónico/metabolismo , Quinolonas/farmacocinética , Anemia/complicaciones , Anemia/tratamiento farmacológico , Animales , Masculino , Quinolonas/uso terapéutico , Ratas , Ratas Wistar
17.
Bioanalysis ; 9(9): 719-732, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28488896

RESUMEN

AIM: A sensitive LC-MS/MS method was developed and validated for estimation of ZYAN1 in human blood/urine. METHODS: An analog internal standard IOX2 along with ZYAN1 was quantified using selective reaction monitoring in positive mode. The chromatographic separation was performed by gradient elution with C18 analytical column (3 µm, 50 mm × 2.0 mm) with 4-min run time using an acidified mobile phase consisting of ammonium formate and acetonitrile. Protein precipitation enabled extraction of analytes from diluted blood/urine. RESULTS: Calibration curve of ZYAN1 was linear (2-5000 ng/ml). The recovery of ZYAN1 and IOX2 was between 87 and 104%. Interday and intraday accuracy and precision was found well within the acceptance criteria. CONCLUSION: The validated assay was applied for clinical pharmacokinetics of ZYAN1 in healthy volunteers.


Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Inhibidores de Prolil-Hidroxilasa/sangre , Inhibidores de Prolil-Hidroxilasa/orina , Quinolonas/sangre , Quinolonas/orina , Espectrometría de Masas en Tándem/métodos , Humanos , Límite de Detección , Reproducibilidad de los Resultados , Espectrometría de Masa por Ionización de Electrospray/métodos
18.
Oncotarget ; 7(22): 33272-85, 2016 May 31.
Artículo en Inglés | MEDLINE | ID: mdl-27120789

RESUMEN

Breast cancer is the leading cause of cancer-associated deaths in women worldwide. Clinical biomarkers give information on disease progression and identify relevant biological pathways. A confounding factor that uncouples markers from disease outcome is the ability of tumor cells to mutate and evade clinical intervention. Therefore, we focussed on apoptotic genes that modulate tumor regression. Using gene and tissue microarray analyses, we identified an association of Bcl-2 interacting killer (Bik) with poor breast cancer prognosis. Bik prognostic ability was independent of Estrogen Receptor/Progesterone Receptor and Her2 status. Additionally, Bik was independent of anti-apoptotic Bcl-2, Bcl-xL, Mcl-1 and Bcl-w suggesting a complex mechanism of tumor promotion identified by Bik high tumors. Bik also stimulates autophagy, which can contribute to enhanced tumor fitness. We found a significant association between the autophagy marker ATG5 and Bik. Combined high expression level of ATG5 and Bik was a stronger predictor of outcome than either alone. Thus, our study identifies Bik as a novel, independent prognostic biomarker for poor outcomes in breast cancer and suggests that Bik-mediated autophagy contributes to disease recurrence.


Asunto(s)
Proteínas Reguladoras de la Apoptosis/análisis , Apoptosis , Biomarcadores de Tumor/análisis , Neoplasias de la Mama/química , Proteínas de la Membrana/análisis , Proteínas Reguladoras de la Apoptosis/genética , Autofagia , Proteína 5 Relacionada con la Autofagia/análisis , Biomarcadores de Tumor/genética , Neoplasias de la Mama/genética , Neoplasias de la Mama/patología , Neoplasias de la Mama/terapia , Progresión de la Enfermedad , Supervivencia sin Enfermedad , Femenino , Perfilación de la Expresión Génica/métodos , Humanos , Estimación de Kaplan-Meier , Proteínas de la Membrana/genética , Persona de Mediana Edad , Proteínas Mitocondriales , Recurrencia Local de Neoplasia , Análisis de Secuencia por Matrices de Oligonucleótidos , Modelos de Riesgos Proporcionales , Factores de Riesgo , Factores de Tiempo , Análisis de Matrices Tisulares , Resultado del Tratamiento , Regulación hacia Arriba
19.
Eur J Med Chem ; 58: 136-52, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23124211

RESUMEN

A novel series of potent and efficacious factor Xa inhibitors which possesses sulfoximine moiety as novel S4 binding element in anthranilamide chemotype has been identified. Lead optimization at this novel P4 group led to many potent factor Xa inhibitors with excellent anticoagulant activity in human plasma. Selected compounds were dosed orally in rats and checked for their ex vivo prothrombin time prolonging activity, which resulted in identification of compound 5-chloro-N-(5-chloropyridin-2-yl)-2-(4-(N-(2-(diethylamino)acetyl)-S-methylsulfonimidoyl)benzamido)benzamide (18f). The detailed pharmacokinetic evaluation and subsequent metabolism study of 18f suggested the presence of an active metabolite. The compound 18f and its active metabolite 18b demonstrated excellent in vivo efficacy in both arterial and venous thrombosis model in rats and were found to be highly selective against related serine proteases. Based on this promising profile, compound 18f was selected for further evaluation.


Asunto(s)
Anticoagulantes/farmacología , Inhibidores del Factor Xa , Iminas/química , Inhibidores de Serina Proteinasa/farmacología , Sulfóxidos/química , ortoaminobenzoatos/farmacología , Animales , Anticoagulantes/administración & dosificación , Anticoagulantes/síntesis química , Anticoagulantes/metabolismo , Sitios de Unión/efectos de los fármacos , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Humanos , Masculino , Modelos Moleculares , Estructura Molecular , Ratas , Ratas Wistar , Valores de Referencia , Serina Proteasas/metabolismo , Inhibidores de Serina Proteinasa/administración & dosificación , Inhibidores de Serina Proteinasa/síntesis química , Inhibidores de Serina Proteinasa/metabolismo , Relación Estructura-Actividad , Trombosis de la Vena/tratamiento farmacológico , Trombosis de la Vena/metabolismo , ortoaminobenzoatos/administración & dosificación , ortoaminobenzoatos/síntesis química , ortoaminobenzoatos/metabolismo
20.
Bioorg Med Chem Lett ; 21(19): 5701-6, 2011 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-21880486

RESUMEN

Two novel series of 5-nitro-2-phenoxybenzoic acid derivatives are designed as potent PAI-1 inhibitors using hybridization and conformational restriction strategy in the tiplaxtinin and piperazine chemo types. The lead compounds 5a, 6c, and 6e exhibited potent PAI-1 inhibitory activity and favorable oral bioavailability in the rodents.


Asunto(s)
Benzoatos/química , Benzoatos/farmacología , Diseño de Fármacos , Descubrimiento de Drogas , Éteres Fenílicos/química , Inhibidor 1 de Activador Plasminogénico/metabolismo , Administración Oral , Animales , Benzoatos/farmacocinética , Disponibilidad Biológica , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Ácidos Indolacéticos/química , Ácidos Indolacéticos/farmacología , Masculino , Estructura Molecular , Éteres Fenílicos/farmacocinética , Éteres Fenílicos/farmacología , Piperazina , Piperazinas/química , Ratas , Ratas Wistar , Relación Estructura-Actividad , Trombosis/inducido químicamente , Trombosis/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA